Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Should Baseline Characteristics Affect Choice of Treatment?

PURPOSE: Among eyes with proliferative diabetic retinopathy (PDR), identify whether baseline characteristics impact the benefit of ranibizumab over panretinal photocoagulation (PRP) in DRCR.net Protocol S. METHODS: Participants had PDR, visual acuity (VA) of 20/320 or better, and no prior PRP. Eyes...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Retina
Glavni autori: Bressler, Susan B., Beaulieu, Wesley T., Glassman, Adam R., Gross, Jeffrey G., Melia, Michele, Chen, Eric, Pavlica, Michael R., Jampol, Lee M.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6698425/
https://ncbi.nlm.nih.gov/pubmed/30807516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IAE.0000000000002377
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items